We have recently identified RFamide-related peptide (RFRP) gene that would encode three peptides (i.e., RFRP-1, -2, and -3) in human and bovine, and demonstrated that synthetic RFRP-1 and -3 act as specific agonists for a G protein-coupled receptor OT7T022. However, molecular characteristics and tissue distribution of endogenous RFRPs have not been determined yet. In this study, we prepared a monoclonal antibody for the C-terminal portion of rat RFRP-1. As this antibody could recognize a consensus sequence among the C-terminal portions of rat, human, and bovine RFRP-1, we purified endogenous RFRP-1 from bovine hypothalamus on the basis of immunoreactivity to the antibody. The purified bovine endogenous RFRP-1 was found to have 35-amino-acid length that corresponds to 37-amino-acid length in human and rat. We subsequently constructed a sandwich enzyme immunoassay using the monoclonal antibody and a polyclonal antibody for the N-terminal portion of rat RFRP-1, and analyzed the tissue distribution of endogenous RFRP-1 in rats. Significant levels of RFRP-1 were detected only in the central nervous system, and the highest concentration of RFRP-1 was detected in the hypothalamus. RFRP-1-positive nerve cells were detected in the rat hypothalamus by immunohistochemical analyses using the monoclonal antibody. In culture, RFRP-1 lowered cAMP production in Chinese hamster ovary cells expressing OT7T022 and it was abolished by pre-treatment with pertussis toxin, suggesting that OT7T022 couples G i /G o in the signal transduction pathway. ß 2001 Elsevier Science B.V. All rights reserved. 
Introduction
A number of bioactive peptides with RFamide structure at their C-termini (e.g., FMRFamide isolated from the bivalve mollusc Macrocallista nimbosa [1] ) have been found particularly in invertebrates, and they are referred to as RFamide peptides [2] . However, in vertebrates, only a few RFamide peptides have been thus far reported. LPLRFamide and gonadotropin-inhibitory hormone (GnIH), have been puri¢ed from chicken and quail brain extracts respectively [3, 4] , but their genes are not identi¢ed yet. Three RFamide peptide genes have been identi¢ed in mammals. One of these codes for two peptides, neuropeptide FF (NPFF) and neuropeptide AF (NPAF), which have been initially characterized to modulate the action of morphine [5, 6] . Another codes for prolactin-releasing peptide (PrRP) which we have identi¢ed as the endogenous ligand of the G protein-coupled receptor (GPCR) hGR3 [7] . Although PrRP was initially demonstrated to have a speci¢c stimulatory activity on the secretion of prolactin (PRL) [8, 9] from rat anterior pituitary cells in vitro and in vivo [7, 10] , to date it has been proven to have a variety of functions [11^14] . We have recently succeeded in the identi¢cation of the other novel mammalian RFamide peptide gene through analyzing human genome and cDNA sequences in the database, and named it RFamide-related peptide (RFRP) gene [15] . By isolating human, bovine, rat, and mouse RFRP cDNAs, we have found that human and bovine RFRP preproproteins encoded by the cDNAs might generate three kinds of mature peptides (i.e., RFRP-1, -2, and -3), whereas those of rodents would generate RFRP-1 and RFRP-3 without RFRP-2. We have subsequently demonstrated that synthetic RFRP-1 and RFRP-3 speci¢cally bind to a novel GPCR, OT7T022, by applying the strategy that we have previously established to identify ligands for orphan GPCRs [16] . The expression of RFRP mRNA has been detected mainly in the eye and hypothalamus, while the highest expression of OT7T022 mRNA has been detected in the hypothalamus in rats. Intracerebroventricular administration of RFRP-1 caused the elevation of plasma PRL levels in rats, suggesting that RFRPs have regulatory functions in PRL secretion.
Although we have demonstrated that RFRPs could speci¢cally interact with OT7T022 in vitro and function even in vivo in rats by utilizing synthetic RFRPs deduced on the basis of the amino acid sequence from the cDNA, there has been no information on the molecular characteristics of endogenous RFRPs. In this study, we prepared antibodies for rat RFRP-1. In our preliminary studies, the contents of immunoreactive RFRP-1 (ir-RFRP-1) in rat brains appeared to be too low level to purify. We hence switched to purify endogenous RFRP-1 from bovine hypothalamic tissue extracts through detecting immunoreactivity with the antibody, and then analyzed the molecular structure of the puri¢ed bovine endogenous RFRP-1. We subsequently analyzed the distribution of ir-RFRP-1 in rat tissues by a sandwich enzyme immunoassay (EIA) and immunostaining. In addition, we con¢rmed the interaction of the endogenous RFRP-1 with OT7T022, and analyzed the intracellular signal transduction mechanism via OT7T022. We believe this is the ¢rst report on analyses for the molecular characteristics and tissue distribution of endogenous RFRP-1.
Materials and methods

Preparation of synthetic peptides
RFRPs and PrRP were synthesized using automatic peptide synthesizer (Model 430, PE Biosystems) as described previously [7, 15] . Human RFRP-1 with 37-amino-acid length (human RFRP-1-37) was also produced by the application of a recombinant DNA technology and Cys-speci¢c cyanylation reaction as described previously [17] . Other peptides were purchased from commercial suppliers (Peptide Institute or Bachem).
Immunological procedures
A monoclonal antibody for the C-terminal portion of rat RFRP-1 was prepared as follows. A synthetic peptide with Cys at the N-terminus (CVPHSAA-NLPLRF-NH 2 : rat RFRP-1C) was conjugated with bovine serum albumin (BSA; Pierce) using N-(Q-maleimidobutyryloxy)succinimide (GMBS; Dojindo). The resultant conjugate at 100 Wg admixed with TiterMax Gold (CytRx corporation) was subcutaneously injected into BALB/c mice (female, 8 weeks old) twice at 2-week intervals. One week after the last subcutaneous injection, 50 Wg of the conjugate was intravenously injected into each mouse. Four days after the intravenous injection, spleen cells obtained from each immunized mouse were fused with mouse myeloma cells (P3-X63Ag8-U1) by using polyethylene glycol 1500 (Boehringer) according to the manufacturer's instruction. A hybridoma clone, 1F3, that produced an antibody for rat RFRP-1C was isolated, and then cultured in an INTEGRA CL-1000 system (Integra Biosciences). The monoclonal antibody produced from 1F3 was puri¢ed from the culture supernatant with a HiTrap rProtein A column (Amersham Pharmacia Biotech). The isotype of the puri¢ed antibody was determined with a Mouse mAb isotyping kit (Amersham Pharmacia Biotech).
Rat RFRP-1C was conjugated with horseradish peroxidase (HRP; Boehringer) using GMBS. After puri¢cation, the HRP-conjugated rat RFRP-1C was puri¢ed, and used as a tracer. For competitive EIA, the puri¢ed 1F3 monoclonal antibody (50 Wl) appropriately diluted with Bu¡er A phosphate-bu¡ered saline (PBS) containing 2 mM EDTA, 0.4% BSA, 0.1 M NaCl, and 0.1% micro-O-protect (Boehringer) was added to each well of goat anti-mouse IgGAMcoated microplates, and then each sample dissolved in Bu¡er A (50 Wl) was added to the well. After incubation at 4³C for 16 h, HRP-conjugated rat RFRP-1C was added to the well, and then the microplates were incubated at room temperature for 2 h. The microplates were washed with PBS containing 0.1% Tween 20 (Sigma) (PBS-T), and then the HRP activity retained in each well was measured with a TMB microwell peroxidase system (Kirkegaard and Perry Labs). As a reference to quantify RFRP-1, we used human RFRP-1 with 12-aminoacid length (i.e., MPHSFANLPLRF-NH 2 ) because both human RFRP-1 and rat RFRP-1C were equally detected by this EIA.
A polyclonal antibody for N-terminal portion of rat RFRP-1 was prepared as follows. A synthetic peptide with Cys at the C terminus (SVTFQELK-DWC: rat RFRP-1N) was conjugated with BSA by the same method as described above. After the resultant conjugate at 300 Wg was admixed with TiterMax Gold, it was subcutaneously injected into rabbits four times at 2-week intervals. Antisera were obtained after the last injection. The IgG fraction of the anti-rat RFRP-1N antibody was then puri¢ed from a proper antiserum through an a¤nity column conjugated with rat RFRP-1N using a SulfLink kit (Pierce).
Rat endogenous RFRP-1 was quanti¢ed with a sandwich EIA using anti-rat RFRP-1N and anti-rat RFRP-C antibodies. The anti-rat RFRP-1N polyclonal antibody was labeled with HRP as described elsewhere [18] . For sandwich EIA, the 1F3 monoclonal antibody was coated to 96-well microplates at 10 Wg/ml in 0.1 M carbonate bu¡er (100 Wl) at pH 9.5. These plates were washed with PBS-T, and each sample dissolved in Bu¡er A (100 Wl) was added to the well. After incubation at 4³C for 24 h, the microplates were washed with PBS-T, and HRP-conjugated anti-rat RFRP-1N Fab was added to each well. After incubation at 4³C for 16 h, the microplates were washed with PBS-T, and then the HRP activity retained in each well was measured with a TMB microwell peroxidase system. As a reference to quantify rat endogenous RFRP-1, we used synthetic rat RFRP-1-37.
Histological procedure is as follows. Under pentobarbital anesthesia, adult male Sprague^Dawley rats injected with 90 Wg colhicine (Nacalai Tesque) into the lateral ventricle 2 days before sacri¢ce were perfused via the left cardiac ventricle with 5% acrolein (Aldrich) in 0.1 M phosphate bu¡er. Serial frozen frontal sections (25 Wm thick) were cut from the brain. The sections were washed with PBS treated with 0.5% sodium pyrosulfate for 10 min, and 1.0% sodium borohydride for 10 min. They were then processed by the avidin^biotin complex immunocytochemical method using the monoclonal antibody 1F3 (20 Wg/ml). Preincubation of the antibody with human RFRP-1-12 diminished the immunoreactivity on the sections.
Extraction of tissues
Frozen bovine hypothalamic tissues (2 kg) were boiled, homogenized in 1 M acetic acid, and extracted overnight. The resultant supernatant was col-lected by centrifugation, and then subjected to various chromatography. Rat tissues were obtained from male or female Wistar rats (8 weeks old) immediately after decapitation, and then frozen at 380³C until used. Plasma was obtained as described elsewhere [19] . Each tissue (0.2^2 g) or plasma was boiled, and then homogenized in 1 M acetic acid. After the centrifugation, the resultant supernatant was desalted with a Sep-Pak Vac C18 column, and then used as a sample for the sandwich EIA.
Chromatography
The bovine hypothalamic extract added with 0.05% tri£uoroacetic acid (TFA) was applied to a Preparative C18 column (Waters), and the elution was performed with step-wise increments of 10%, 30%, and 50% CH 3 CN with 0.1% TFA. The contents of ir-RFRP-1 were determined with the competitive EIA using the monoclonal antibody 1F3. Ir-RFRP-1-positive fraction was eluted in 30% CH 3 CN. It was further fractionated by a HiPrep CM-Sepharose FF (Amersham Pharmacia Biotech) column with stepwise increments of 0.1, 0.2, 0.5, and 1.0 M NaCl in 20 mM CH 3 COONH 4 (pH 4.7) containing 10% CH 3 CN. After precipitation with acetone, the 0.2 M CH 3 COONH 4 fraction was serially fractionated on a Resource RPC column (Amersham Pharmacia Biotech) with a linear gradient from 10% to 30% CH 3 CN with 0.1% TFA, and a TSK-gel CM-2SW column (Toso) with a linear gradient from 0.2 to 0.6 M NaCl in 20 mM CH 3 COONH 4 at pH 4.7. The fractions containing ir-RFRP-1 were subsequently fractionated on a Vydac diphenyl 219TP52 column (Separation Corp.). Ir-RFRP-1 was eluted in fractions at 23% in a linear gradient from 21% to 25% CH 3 CN with 0.1% TFA. The fractions containing ir-RFRP-1 were ¢nally applied to a WRPC C2/C18 SC 2.1/10 column (Amersham Pharmacia Biotech) in SMART system (Amersham Pharmacia Biotech).
Tissue samples for gel ¢ltration were collected as follows. Acetic acid extracts obtained from ten rat brains were applied to a Sep-Pak Vac C18 column, and then eluted with step-wise increments of 10%, 30%, and 50% CH 3 CN containing 0.1% TFA. The fraction eluted with 30% CH 3 CN was diluted with twofold volume of 20 mM CH 3 COONH 4 at pH 4.7, and then applied to a HiTrap CM-Sepharose FF 5-ml column (Amersham Pharmacia Biotech). Elution from CM-Sepharose was performed with a linear gradient from 0 to 500 mM NaCl in 20 mM CH 3 COONH 4 at pH 4.7 containing 10% CH 3 CN. Ir-RFRP-1-positive fractions were precipitated with threefold volumes of acetone, and then applied on gel ¢ltration chromatography using a Superdex Peptide PC 3.2/30 column in SMART system (Amersham Pharmacia Biotech) in 40% CH 3 CN containing 0.1% TFA at a £ow rate of 25 Wl/min.
Peptide sequencing and mass spectrometry
The N-terminal sequence of the puri¢ed peptide was determined using a Model 491 cLC protein sequencer (PE Biosystems). Electrospray ionization (ESI) mass spectrometry was performed on a LCQ ion-trap mass spectrometer (ThermoQuest) equipped with a nanoESI source (Protana). The puri¢ed peptide was dissolved in 50% (v/v) CH 3 CN with 1% HCOOH, and then loaded into a gold-coated capillary (Protana). ESI conditions were as follows: capillary temperature, 160³C; ESI voltage, 1.5 kV; capillary voltage, 46 V. The molecular mass of the peptide was calculated using a Bioworks software (ThermoQuest).
cAMP production assay
We prepared Chinese hamster ovary (CHO) cells transfected with human OT7T022 cDNA, and then examined the inhibitory activities of samples on cAMP production in these cells in the presence of forskolin according to the method as described previously [15, 20] . For the treatment of pertussis toxin (PTX), these cells were incubated with 100 ng/ml of PTX (P-9480, Sigma Chemical Co.) overnight before the cAMP production assays.
Results
Construction of competitive EIA using anti-rat RFRP-1C antibody
To detect endogenous bovine RFRP-1, we prepared a mouse monoclonal antibody (1F3 with IgG1 heavy and U light chains) that was capable of recognizing C-terminal portion of rat RFRP-1, and then constructed a competitive EIA using this antibody and HRP-conjugated rat RFRP-1 C-terminal fragment as a tracer. As shown in Fig. 1 , this EIA could e¤ciently detect both human RFRP-1-12 and LPLRFamide. It could also detect the non-amidated form of LPLRF and Met-Enkephalin-RFamide (i.e., YGGFMRF-NH 2 ), though the e¤cacy of the detection evidently decreased. However, it did not detect other peptides with C-terminal RFamide, that is, bovine NPFF (i.e., FLFQPQRF-NH 2 ) and NPAF (i.e., AGEGLSSPFWSLAAPQRF-NH 2 ) or human RFRP-3 with 8-amino-acid length (i.e., VPNLPQ-RF-NH 2 : RFRP-3-8). These results indicate that this EIA principally detects the C-terminal portion of rat RFRP-1, probably the epitope of LPLRF-NH 2 , which is a consensus sequence among bovine, rat and human (Fig. 2) . We thus decided to employ this EIA to detect endogenous RFRP-1 in the process of the puri¢cation from bovine hypothalami.
Puri¢cation of endogenous bovine RFRP-1
RFRP mRNA has been demonstrated to be mainly expressed in the hypothalamus in rats [15] . However, it was di¤cult to collect rat hypothalamus in a large quantify su¤cient to purify endogenous RFRP-1. We thus employed bovine hypothalamic tissues as a starting material to purify endogenous RFRP-1. Puri¢cation was performed with a combination of various chromatography through monitoring ir-RFRP-1 with the competitive EIA. Fig. 3 shows the pro¢le of the last chromatography with a reverse-phase HPLC using a WRPC C2/C18 SC 2.1/10 column. Ir-RFRP-1 was eluted as a single peak in a gentle linear gradient from 22% to 23% CH 3 CN with 0.1% TFA, and this peak coincided with that of absorbance at 215 nm. We eventually obtained 58 pmol of the puri¢ed RFRP-1. The fraction containing puri¢ed RFRP-1 was subjected to microsequencing and mass spectrometry. The microsequencing revealed the following N-terminal sequence: SLTFEEVKDXAPKIKMNKPV (X was ambiguous due to low yield of the PTH-amino acid) (Fig. 4A) , corresponding to the sequence from Ser58 to Val77 in the bovine RFRP preproprotein (Fig. 2) . The molecular mass of the puri¢ed RFRP-1 was determined to be 3996.8 þ 0.6 with mass spectrometry (Fig. 4B) . This value agreed with the calculated molecular mass of 3996.8 in the amidated form of RFRP-1 with 35-amino-acid length that would generate from Ser58 to Phe92 from the bovine RFRP preproprotein (Fig. 2) . These results indicate that the puri¢ed bovine RFRP-1 consists of the following amino acid residues: SLTFEEVKDWAPKI-KMNKPVVNKMPPSAANLPLRF-NH 2 .
3.3. Construction of sandwich EIA to quantify rat endogenous RFRP-1
To quantify precisely endogenous rat RFRP-1, we prepared a rabbit polyclonal antibody for the N-terminal sequence (i.e., SVTFQELKDW) of rat RFRP-1-37. This antibody could recognize rat RFRP-1-37, but not other RFamide peptides including human RFRP-1-37, NPFF, and NPAF (data not shown). (7), were added to the well, respectively. After incubation for 16 h, HRP-conjugated rat RFRP-1C was added to the well, and then the plates were incubated for 2 h. After the plates were washed, the HRP activity retained in each well was measured. Data are expressed as means in duplicate assays. B, absorbance in the presence of samples; B0, that in the absence of samples.
By utilizing this polyclonal antibody labeled with HRP and the monoclonal antibody for the C-terminal portion of rat RFRP-1, we constructed a sandwich EIA to quantify rat endogenous RFRP-1. This sandwich EIA could detect at least 0.4 fmol/well of rat RFRP-1-37. However, it did not detect other peptides with the RFamide structure, including human RFRP-1-37, human RFRP-1-12, LPLRFamide, Met-Enkephalin-RFamide, NPFF, and NPAF (data not shown). These results indicate that this EIA can detect speci¢cally rat RFRP-1-37.
Analysis for distribution of RFRP-1 in rat tissues
We measured the contents of endogenous RFRP-1 in rat tissues with the sandwich EIA. As shown in Fig. 5 , signi¢cant levels of ir-RFRP-1 were detected principally in the central nervous system, and the highest concentration was detected in the hypothalamus (2800 fmol/g wet tissue). High concentrations of ir-RFRP-1 were detected in the thalamus (1000 fmol), midbrain (880 fmol), and optic nerve (440 fmol). Moderate levels of ir-RFRP-1 were detected in the cerebral cortex (140 fmol), striatum (210 fmol), and medulla oblongata (250 fmol), and low levels in the hippocampus (29 fmol) and cerebellum (33 fmol). However, it was undetectable ( 6 2.1 fmol) in the peripheral tissues including plasma.
To analyze more detailed distribution of RFRP-1 in the hypothalamus, we conducted immunohistochemical analyses using the monoclonal antibody 1F3. We used the acrolein ¢xation method because we obtained better speci¢c signals by acrolein than by paraformaldehyde. As shown in Fig. 6 , ir-RFRP-1 was detected in neurons and ¢bers within the caudal portion of the hypothalamus; the periventricular nucleus (PerVN) and the portion around or above the ventromedial nucleus (VMN) of the hypothalamus. More precise location of neurons with ir-RFRP1 was between VMN and dorsomedial nucleus DMN and extended to the lateral hypothalamic area.
Analysis for molecular characteristics of endogenous rat RFRP-1
We analyzed the molecular size of endogenous RFRP-1 in the rat brain by gel ¢ltration in combination with the competitive EIA. Acetic acid extracts from the rat brain were partially puri¢ed, and then subjected to the EIA. In a HiTrap CM-Sepharose FF column chromatography, the immunoreactivities were detected separately in a minor peak of P1 and a major peak of P2 (data not shown). After fractions containing P1 and P2 were treated with acetone, the resultant supernatants were respectively applied to a Superdex peptide PC 3.2/30-column chromatography. In P1 ir-RFRP-1 was eluted at the position corresponding to human RFRP-1-12 (Fig. 7A) , whereas in P2 it was eluted at that corresponding to rat RFRP-1-37 (Fig. 7B) . By the sandwich EIA, we could detect ir-RFRP-1 only in P2 but not in P1 (data not shown). Thus we could not rule out the possibility that P1 might contain substances unrelated to RFRP-1. These results indicate that the major component of endogenous rat RFRP-1 is rat RFRP-1-37.
Interaction of endogenous RFRP-1 with OT7T022
We prepared CHO cells expressing human OT7T022 and examined the interaction of endogenous RFRP-1 with OT7T022. As shown in Fig. 8 , both synthetic rat RFRP-1-37 and human RFRF-1-37 e¤ciently inhibited cAMP production in these cells stimulated with forskolin (i.e., e¡ective doses of 50% (ED 50 ) at 30 and 21 nM, respectively). Their potency was comparable with LPLRFamide (ED 50 at 36 nM) but less than human RFRP-1-12 (ED 50 at 4.5 nM) or human RFRP-3-8 (ED 50 at 9.9 nM) and greater than NPFF (ED 50 at 140 nM) and PQRFamide (ED 50 at s 1000 nM). They showed almost comparable activity on CHO cells expressing rat OT7T022 in this assay (data not shown). Synthetic human RFRP-2 with 12-amino-acid length (RFRP-2-12) did not show agonistic activity on OT7T022. These results indicate that the endogenous type of RFRP-1 certainly acts as a speci¢c agonist for OT7T022.
To elucidate the mechanism for the inhibition of cAMP production, we treated these cells with PTX. As shown in Fig. 9 , the inhibition of cAMP production induced by human RFRP-1-12 was almost completely abrogated by the pre-treatment with PTX.
Discussion
In this study, we puri¢ed endogenous bovine RFRP-1 and determined its structure. The puri¢ed endogenous bovine RFRP-1 was found to consist of 35 amino acid residues. This result indicates that the N-terminus of the mature bovine RFRP-1 is produced by cleavage between Arg56 and Ser57 in the bovine RFRP preproprotein (Fig. 2) . As basic amino acid residues are generally considered to be potential sites receiving cleavage by proteases, this cleavage appears to be rational in this point. However, in the sequence of the endogenous bovine RFRP-1, there are other ¢ve basic amino acid residues, that is, Lys64, 69, 71, 74, and 79 (Fig. 2) . It was thus unexpected that endogenous RFRP-1 had a long N-terminal portion. In the puri¢cation process, we could not detect shorter forms of endogenous bovine RFRP-1 at least as major components. Although we do not know the reason why the cleavage occurs selectively between Arg56 and Ser57, a three-dimensional conformation might in£uence the susceptibility of respective sites to proteases. To be interested, the two amino acid residues (Arg and Ser) at the cleavage site were completely conserved among mammalian species [15] . These results suggest that a similar processing to produce endogenous bovine RFRP-1 occurs in other species, that is, RFRP-1 molecules with 37-amino-acid length generate from the human, rat, and mouse preproproteins.
As we have reported previously [15] and showed in this study, shorter C-terminal RFRP-1 peptides (i.e., human RFRP-1-12) had su¤cient agonistic activities on OT7T022. These results indicate that a core structure to interact with the receptor resides in the C-terminal portion. We have recently reported that a bioactive peptide, apelin, has 36-amino-acid length as a main endogenous form and its core structure to interact with the receptor (APJ) resides within the C-terminal 13 residues [21] . We have demonstrated that the long N-terminal portion of apelin functions to modulate the interaction with the receptor [22] . Further studies will be necessary to reveal the function of the long N-terminal portion of RFRP-1. In addition, we found that the RFRP-1-induced inhibition of cAMP production in CHO cells expressing OT7T022 was abolished by the treatment with PTX. These results suggest that OT7T022 couples to G i /G o .
By the sandwich EIA speci¢c for rat RFRP-1-37, we revealed the tissue distribution of endogenous RFRP-1 in rat tissues. Ir-RFRP-1 was detected mainly in the central nervous system. The highest concentration of ir-RFRP-1 was detected in the hypothalamus, and high levels of ir-RFRP-1 in the thalamus and midbrain. We con¢rmed the distribution of endogenous RFRP-1 in the hypothalamus by immunostaining with the monoclonal antibody 1F3. In this analysis, we found that ir-RFRP-1-positive cell bodies were distributed in the PerVN and VMN. These results agreed well with our previous data that RFRP mRNA is highly expressed in the PerVN and VMN in rats. In addition, we detected ir-RFRP-1-positive nerve ¢bers in the hypothalamus, suggesting that processes from neurons producing RFRP-1 are distributed in various regions in the brain. We are now under investigation in this point. We have previously reported that a high level of RFRP mRNA is detectable in the eye in addition to the hypothalamus in rats [15] , but we could not detect a signi¢cant amount of ir-RFRP-1 in the eye by the EIA in this study. In addition, even in the immunohistochemical analysis using the monoclonal antibody 1F3, we could not detect evident ir-RFRP-1 in the retina. The discrepancy in the distribution of RFRP mRNA and ir-RFRP-1 in the eye still remains to be resolved. On the other hand, OT7T022 mRNA has been detected not only in the central nervous system but also in the testis [15] . However, we detected neither ir-RFRP-1 nor RFRP mRNA at signi¢cant levels in the testis. These results indicate that RFRPs do not function in the testis, although we cannot rule out the possibility that other RFamide peptides act on OT7T022 in this tissue.
As we have previously pointed out, the sequences of NPFF, NPAF, and RFRPs are closely related. Several groups have very recently reported the identi¢cation of receptors for NPFF and NPAF. A GPCR, HLWAR77, has been reported to act as a speci¢c receptor for NPFF and NPAF [23] . HLWAR77 is nearly identical to NPGPR previously reported by another group [24] . It has been also reported that there are two receptors (i.e., NPFF1 and NPFF2) for NPFF [25] . HLWAR77/NPGPR is identical to NPFF2, while OT7T022 is identical to NPFF1. However, the binding a¤nity of NPFF on OT7T022/NPFF1 is reportedly less than that on HLWAR77/NPGPR/NPFF2 [25] . As shown in this study, the agonistic activity of NPFF on OT7T022 appeared to be less than RFRPs in the cAMP-production-inhibitory assay using CHO cells, suggesting that RFRPs principally work as ligands for OT7TO22. Future studies to determine the cross reactivity of RFRPs on HLWAR77/NPGPR/NPFF2 and OT7T022/NPFF1 will be necessary.
As we have previously reported [15] , the sequence of the chicken LPLRFamide [3] completely matches with the C-terminal sequence of RFRP-1. In addition, an RFamide peptide, GnIH [4] , which has been recently isolated from the quail brain, has a very similar sequence (i.e., SIKPSAYLPLRF-NH 2 ) to the C-terminal portion of RFRP-1. The amino acid sequence similarity among LPLRFamide, GnIH, and RFRP-1 strongly suggest that these peptide genes have evolved and diversi¢ed from the same ancestor.
We have showed that the administration of human RFRP-1-12 into the rat third ventricle induces the elevation of plasma PRL levels [15] . NPFF, NPAF, and PrRP reportedly have a variety of biological activities [26,27,11^14] . Therefore, there is the possibility that RFRPs also have various unknown functions. LPLRFamide reportedly elevates arterial blood pressure and induces excitation in neurons in rats [3, 28] . GnIH reportedly inhibits luteinizing hormone secretion in primary-cultured quail pituitary cells [4] . Future studies are required to determine whether RFRPs have similar functions to LPLRFamide or GnIH.
In this study, we demonstrated the existence of endogenous RFRP-1 and clari¢ed its structure and distribution. However, the molecular characteristics of endogenous RFRP-2 and -3 remain to be elucidated. Further studies on RFRP and its receptor will give insight into the physiological signi¢cance of RFamide peptides in mammals.
